Nona, Lonza Partner on BBB Technology for CNS Therapies
CAMBRIDGE, Massachusetts, July 1, 2026 Nona Biosciences has entered into a strategic collaboration with Lonza to develop a next-generation...
CNS Therapeutics
Advertisement
BioArctic, Lilly Partner on Next-Gen Brain Therapies
STOCKHOLM, Sweden, June 22, 2026 BioArctic AB and Eli Lilly and Company have entered into a major research and...
Insilico Medicine and SK Bio Launch $2.5B CNS Alliance
BOSTON, MA and SEOUL, South Korea, June 22 2026 Insilico Medicine and SK Biopharmaceuticals have announced a landmark artificial...
Teva Advances Schizophrenia Therapy in Europe
TEL AVIV, Israel & PARIS, May 21, 2026 Teva Pharmaceuticals and Medincell have announced that the European Medicines Agency...
Fosun Pharma Signs Global Option Deal for AriBio’s AR1001
SHANGHAI and SEONGNAM-SI, South Korea, May 13, 2026 Fosun Pharma and AriBio announced the signing of an exclusive global...
Advertisements
AI Drug Discovery Deal Expands CNS Pipeline Value
Hong Kong | March 30, 2026 AI Collaboration Accelerates CNS Drug Discovery Insilico Medicine and Tenacia Biotechnology have announced...
Lupin Launches Topiramate ER Capsules in United States
MUMBAI, India & NAPLES, Fla., Feb. 4, 2026 — Global pharmaceutical company Lupin Limited announced the U.S. launch of...
Contineum Secures $90M Funding to Advance CNS Drug Pipeline
BOSTON, December 12, 2025 — Contineum Therapeutics, Inc. announced the pricing of an upsized $90.0 million public offering of...
FDA Clears Path Forward for Vanda’s Motion-Sickness Drug Development
WASHINGTON, D.C., December 4, 2025 — The U.S. Food and Drug Administration (FDA) has lifted its partial clinical hold...
FDA Clears Jupiter Neurosciences’ JOTROL™ for Phase 2a Parkinson’s Trial
JUPITER, Florida, November 5, 2025 — Jupiter Neurosciences, Inc. (NASDAQ: JUNS), a clinical-stage biopharmaceutical company, announced that the U.S....
Advertisement
